IOLCP IOL Chemicals and Pharmaceuticals Q1 FY27 results (Apr–Jun 2026) and concall
IOL Chemicals and Pharmaceuticals Limited reported a strong Q1 FY27, with revenue growing 37% YoY to ₹756 crores and PAT surging 89.9% to ₹64.5 crores. This performance was driven by healthy demand, improved capacity utilization, and a favorable product mix, particularly from the growing non-ibuprofen portfolio. The company's strategic focus on diversification and operational efficiencies led to significant margin expansion, with EBITDA margin reaching 14.6%.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q1 FY27: revenue up 37.0%, net profit up 88.2% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 526 | 523 | 528 | 552 | 568 +8% | 580 +11% | 619 +17% | 756 +37% |
| EBITDA | 42 | 47 | 63 | 62 | 57 +36% | 57 +21% | 93 +48% | 104 +68% |
| Net profit | 19 | 21 | 32 | 34 | 30 +58% | 21 +0% | 53 +66% | 64 +88% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
